The Surveillance and Epidemiology of Drug-resistant Infections Consortium (SEDRIC) is a think tank designed to bring together a range of international experts to share expertise and take action to tackle the gaps in drug-resistant infection surveillance and epidemiology.

Our mission and aims

Theory of Change

SEDRIC is a think tank with global representation promoting the power of high quality data to tackle Antimicrobial Resistance, made possible through funding support from Wellcome and thanks to input from experts in epidemiology, surveillance, infectious disease and global health. SEDRIC aims to support improvements in data capture and exchange in order to advise public health practitioners, increase AMR awareness and inform funding strategies for AMR surveillance and epidemiology.

SEDRIC approaches the challenge of AMR through three main strategies:

  • Our working groups bring together a wide range of experts who provide technical analysis.
  • Through our publications, summary papers and consultancy we generate high quality advice.
  • Our global meetings, social media presence and tools for strategy allow SEDRIC to play an important role in AMR advocacy.

SEDRIC produces recommendations to bring about sustainable policy change and practice. Through our social media platforms and engagement activities (working groups, workshops and global meetings), SEDRIC has created a pool of international members to raise awareness on current gaps and promote sustainable solutions in surveillance and epidemiology.

Through these activities we convene experts in AMR surveillance and epidemiology to share knowledge. We listen to our member experts in order to move forward with our analysis and identification of gaps and solutions. We learn from one another so we can ensure we are best placed to offer expert recommendations.

What we aim to achieve

The Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) focuses on producing outcomes which lead to stronger, more resilient health systems. This means influencing changes in policy, practice and funding in surveillance and epidemiology of drug resistant infections.

What we create

What we produce is focused on generating evidence based action both nationally and globally. This means producing evidence, running campaigns and generating recommendations for policy makers.

What we do

Our activities fall into three categories; analysis, advice, and advocacy. Within each of these categories a range of activities (working groups, publications, board meetings) reflect context specific needs and gaps.

Our core principles

Everything we do we do collaboratively. SEDRIC is a network built on convening expertise, listening, and learning.

How we are funded

SEDRIC is currently funded by Wellcome and receives support from the Drug Resistant-infections Priority Area team at Wellcome. Wellcome does not participate in the day-to-day governance of SEDRIC, but it is involved in appointing of SEDRIC board members.

Please note, SEDRIC is not a funding body and does not provide funding to other organisations or individuals.


“We know that good data will be essential if we are to successfully tackle drug-resistant infections, but what is also essential is that these data are available to those who need it. At SEDRIC we want to identify where gaps in data exist, what the barriers are preventing its full use and advocate for how these can be overcome at a national and international level. We coordinate expertise on surveillance and epidemiology from around the globe to advocate for better practices in all settings. We rely on the expertise of clinicians, microbiologists, vets and many others from all over the world to take an active role in contributing to our work and that is why our membership is so important.”

Sharon Peacock, SEDRIC Chair.

“Wellcome is proud to support the important work being done by SEDRIC. Progress to effectively control drug-resistant infections will reuire evidence-informed decisions. Having good, openly accessible data is central to Wellcome’s strategy to tackle antimicrobial resistance (AMR) globally.  We must be able to inform data collection systems on where gaps exist and how to overcome existing barriers to collection so that data is available to inform treatment of patients and the public health response to AMR. This is why SEDRIC’s work will be invaluable in the global effort to stop superbugs.”

Tim Jinks, Head of Drug-Resistant Infections, Wellcome.

“Global action on antimicrobial resistance must be informed by good quality data that is available at the global, national and local level. SEDRIC identifies barriers to evidence-based decision making and advocates for more effective surveillance and epidemiology of drug-resistant infections. I fully support this important work, which is crucial if we are to stop superbugs.”

Sally Davies, UN Special Envoy on AMR, former Chief Medical Officer for England and Wales

How we are governed

SEDRIC has two governing entities:

The Board

Comprised of a chairperson and antimicrobial resistance (AMR) surveillance and epidemiology experts, the Board sets SEDRICs agenda and objectives, produces publications and holds votes on SEDRIC matters.

The Secretariat

The Secretariat is responsible for organising board meetings, implementing the board’s recommendations, supporting working groups, managing SEDRIC membership and running SEDRIC’s day-to-day operations.

Board members

The SEDRIC board has 11 members, with expertise spanning genetics, epidemiology, microbiology, public health and animal health. The current chair is Professor Nick Feasey.

The board will commission reviews and convene fixed-term working groups to address key issues in the fight against drug-resistant infection. This could include how to develop guidelines and tools to encourage data sharing, or how to translate scientific evidence into policy.

Nick Feasey (Chair)

Professor, Liverpool School of Tropical Medicine

Nick Feasey is a clinician academic and Professor of Microbiology at the Liverpool School of Tropical Medicine. He is a consultant in medical microbiology and clinical infectious disease and he is based at the Wellcome Major Overseas Programme in Blantyre, Malawi, the “Malawi Liverpool Wellcome Trust Clinical Research Programme” (MLW)

His research is focused on the surveillance and management of bacterial bloodstream infection, and taking a one health approach to exploring the transmission of enteric pathogens and associated antimicrobial resistance determinant using genomics, spatial statistics and transmission modelling in collaboration with the Wellcome Trust Sanger Institute and CHICAS at the University of Lancaster.

Sharon Peacock

Professor of Public Health and Microbiology at the University of Cambridge, and Director of the COVID-19 Genomics UK (COG-UK) Consortium.

Sharon is an academic clinical microbiologist at the University of Cambridge and the Wellcome Sanger Institute. She became the Executive Director and Chair of the COVID-19 Genomics UK (COG-UK) consortium (https://www.cogconsortium.uk) in April 2020. This was created to deliver large-scale and rapid whole-genome virus sequencing to local NHS centres and the UK government. COG-UK is made up of an innovative partnership of NHS organisations, the four Public Health Agencies of the UK, the Wellcome Sanger Institute and over twelve academic partners providing sequencing and analysis capacity. The virus genome data is combined with clinical and epidemiological datasets in order to help to guide UK public health interventions and policies.

In the decade prior to this, Sharon undertook research into the clinical and public health applications of pathogen sequencing, focusing on hospital-associated, antibiotic-resistant pathogens including MRSA (methicillin-resistant Staphylococcus aureus) and vancomycin-resistant Enterococcus faecium. Her group also use big data to explore biological processes relating to host-pathogen interactions. 

Sharon is a non-executive director at Cambridge University Hospitals NHS Foundation Trust. She is a Fellow of the Academy of Medical Sciences, a Fellow of the American Academy of Microbiology, and an elected Member of EMBO. She was awarded a CBE for services to medical microbiology in 2015 and won the Unilever Colworth Prize for outstanding contribution to translational microbiology in 2018.

Rogier van Doorn

Director, Oxford University Clinical Research Unit, Vietnam

Rogier is a clinical microbiologist from the Netherlands who has worked in Vietnam since 2007. Rogier first headed the emerging infections group at the Oxford University Clinical Research Unit in Ho Chi Minh City. In 2015 he became director of the OUCRU unit in Hanoi.

In Hanoi, Rogier leads a community cohort for the study of human influenza. The OUCRU unit hosts a multidisciplinary research programme on antimicrobial resistance, including a Fleming Fund pilot investment. The programme includes laboratory diagnostics, new resistance mechanism discovery, clinical intervention trials and policy influencing with the responsible ministries.

Keiji Fukuda

Clinical Professor and Director, School of Public Health, University of Hong Kong

Keiji is Director and Clinical Professor of the School of Public Health at the University of Hong Kong. Previously, he worked at the World Health Organization, where his roles included Assistant Director-General for Health Security and the Environment, Special Representative for Antimicrobial Resistance for the Director-General, and Director of the Global Influenza Programme. He was also epidemiology section chief and a medical epidemiologist at the US Centers for Disease Control and Prevention. 

Keiji has helped shape the global approach to responding to emerging infectious diseases (such as influenza, SARS, MERS and Ebola), antimicrobial resistance and pandemic preparedness. He was instrumental in the development and adoption of the Pandemic Influenza Preparedness Framework and the implementation of the International Health Regulations. 

He has considerable experience in epidemiology and field investigations, media communications and international diplomatic negotiations. He had central roles in establishing the 2015 Global Action Plan for Antimicrobial Resistance and the 2016 high-level meeting on antimicrobial resistance held by the United Nations General Assembly.

Alison Holmes

Professor of Infectious Diseases, Imperial College London

Alison has a longstanding clinical and research career in infectious diseases, with particular interests in antibiotic use, antimicrobial resistance, epidemiology and public health.

She leads a large multidisciplinary research group and network, which collaborates nationally and internationally. She is Director of the NIHR Health Protection Research Unit in Healthcare-Associated Infections and Antimicrobial Resistance. She sits on a variety of World Health Organization expert groups, on the Executive Committee of the International Society of Infectious Diseases, and chairs or sits on numerous international scientific advisory boards, funding panels and editorial boards. 

In the NHS, she is Associate Medical Director, Director of Infection Prevention and Control, and a consultant in infectious diseases. She served as an expert member of the Governmental Advisory Committee on Antimicrobial Resistance and Healthcare-Associated Infection for nine years. 

Direk Limmathurotsakul

Head of Microbiology at Mahidol Oxford Tropical Medicine Research Unit

Direk has been the Head of Microbiology at MORU, a research collaboration between Mahidol University, the University of Oxford and Wellcome, since January 2012. He holds a Wellcome Intermediate Fellowship in Public Health and Tropical Medicine. He also runs his own fellowship-funded research programme on reducing the global burden of melioidosis. 

Direk’s main research areas are melioidosis and antimicrobial resistance. He is also interested in public engagement and influencing policy change at a local and global level. He sits on the Thailand National Action Plan on Antimicrobial Resistance working committee. 

By integrating routinely collected data from a range of databases, Direk has estimated that around an extra 19,000 deaths are caused by multi-drug resistant bacteria in Thailand each year. He has also estimated the antibiotic footprint of chicken meat in Thailand and proposed that labels on retail packs of meat should include data on antibiotic use. 

Iruka N Okeke

Professor of Pharmaceutical Microbiology at University of Ibadan, Nigeria

Iruka’s laboratory studies the molecular epidemiology, pathogenesis and antimicrobial resistance of enteric bacteria. She also researches biomedical laboratory practice in Africa. 

Iruka has served as a consultant on drug resistance in Africa for a number of organisations, including the Alliance for Prudent Use of Antibiotics, the Center for Global Development, the Nigerian and US Centers for Disease Control and Prevention, the United States Pharmacopoeia and the World Health Organization. 

She is the author of ‘Divining Without Seeds: The case for strengthening laboratory medicine in Africa’ (Cornell), and ‘Genetics: Genes, Genomes and Evolution’ (Oxford). She is the editor-in-chief of the African Journal of Laboratory Medicine.

Tony Fiore

Chief, Epidemiologic Research and Innovations Branch, CDC

Anthony (Tony) Fiore, MD, MPH, is a medical epidemiologist and infectious diseases physician. Since January 2015 he has been Chief of the Epidemiology Research and Innovations Branch, Division of Healthcare Quality Promotion, leading projects aimed at preventing or reducing healthcare-associated infections and sepsis. He holds the rank of Captain in the Commissioned Corps of the United States Public Health Service, and is board certified in infectious diseases.

Since coming to CDC in 1995 as an Epidemic Intelligence Service (EIS) officer, he has worked on respiratory diseases, viral hepatitis, and seasonal and pandemic influenza. Work on healthcare-related illness includes investigations of nosocomial outbreaks of respiratory disease and viral hepatitis, as well as healthcare worker vaccination issues. Deployments for emergency responses include the anthrax, SARS, Hurricane Katrina, Ebola, and cholera transmission in Haiti. Most recently, he was a member of the team that developed and implemented a training program for U.S. clinicians deploying to West African Ebola Treatment Units.

Stuart Reid

Principal at Royal Veterinary College

Stuart is Principal of the Royal Veterinary College (RVC) at the University of London. An alumnus of the University of Glasgow, he became one of its youngest professors in 1996 and dean in 2005, before moving to the RVC in 2011.

Stuart is recognised as a specialist in veterinary epidemiology by the Royal College of Veterinary Surgeons (RCVS) and in veterinary public health by the European Board of Veterinary Specialists. He is a Fellow of the Royal Society of Biology and the Royal Society of Edinburgh. His research interests include zoonotic disease and antimicrobial resistance. 

Stuart was President of the RCVS in 2014-15, a year which saw the launch of a new Royal Charter, the introduction of the courtesy title of ‘Dr’ for UK veterinarians, and an overhaul of the organisation’s 50-year old governance structures. Two major initiatives – Vet Futures and Mind Matters – were also launched. In 2015, Stuart ran the London marathon, raising £14k and awareness for mental health issues in the profession.

In his public service, he has been a trustee of The Donkey Sanctuary since 1996, and Chairman of trustees since 2007. He is a trustee of the University of London and sits on the board of the Food Standards Agency in the UK.

Nandini Shetty

Clinical Microbiologist at University College London Hospitals and Public Health England

Nandini is a clinical microbiologist at University College London Hospitals and Public Health England. She is Deputy Director of the World Health Organization Collaborating Centre for Reference and Research on Antimicrobial Resistance and Healthcare-Associated Infections. 

Nandini has been working with WHO Europe on projects to build antimicrobial resistance laboratory capacity in low- and middle-income countries (LMICs). She has delivered training at multi-LMIC workshops to build laboratory capacity for participation in the Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR) programme. 

She has worked with LMICs in Central Asia and Eastern Europe to facilitate the development of national action plans to combat antimicrobial resistance, and antimicrobial stewardship and infection prevention and control programmes. 

Jyoti Joshi

Head of South Asia at the Center for Disease Dynamics, Economics & Policy

Jyoti Joshi MD MSc is Head – South Asia at the Center for Disease Dynamics, Economics & Policy (CDDEP). She is a medical doctor specialized in Community Medicine and is an Adjunct Professor at Amity Institute of Public Health, Amity University, Noida, India.

Jyoti co-authored the Scoping Report on the antimicrobial resistance research landscape in India and as the Asia lead for the Global Antibiotic Research Partnership (GARP) project, she supports LMIC countries in Asia to develop and implement national action plans and develop policies to combat antimicrobial resistance. She has supported AMR Situation Analyses in Pakistan, Laos, and Bangladesh and advised the World Health Organisation for country case studies to explore ways to integrate AMR action plans into existing health programs. This contributed to the development of the WHO working paper ” Turning plans into action for antimicrobial resistance”: Jyoti is undertaking large multi-disciplinary research projects in India: first to explore potential for smart regulations for antibiotic use in India using a one health approach and another, to map the drivers of antimicrobial resistance in poultry in India.

Prior to CDDEP, Jyoti has worked with the Immunization Technical Support Unit, Ministry of Health and Family Welfare and the Ministry of Health, United Arab Emirates. Jyoti played a key role in strengthening the Adverse Events Following Immunization (AEFI) Surveillance system and establish the Secretariat for the National Technical Advisory Group on Immunization(NTAGI) in India. Her work contributed to strengthening immunization policy and several new vaccine introductions in India and UAE.

Gemma Buckland Merrett

Science Lead Drug Resistant Infections at Wellcome Trust

Dr Gemma Buckland Merrett is the Science Lead for Drug-Resistant Infections priority programme at Wellcome. In her role, she is shaping and delivering Wellcome’s antimicrobial resistance strategy, bridging the gap between science and policy.  

Gemma joined Wellcome in 2019 from Public Health England where she was the lead epidemiologist for travel-associated infections. Gemma has over ten years of experience in multi-disciplinary research roles leading projects spanning public health, epidemiology and infectious diseases.  She worked as a research manager for Health Action International, an NGO focused on access to medicines, where she led a multi-country research project on access to sexual and reproductive health commodities in Africa. Prior to this Gemma spent four years in academic research at the University of Sussex Centre for Global Health Policy focusing on antimicrobial resistance and access to medicines.  

Gemma has a PhD in Immunology from Imperial College, an MSc in Global Health and Development from University College London and an MSc in Controlling Infectious Diseases from the London School of Hygiene and Tropical Medicine.  

Mirfin Mpundu

Head of Antibiotic Resistance (ReAct) Africa

Mirfin Mpundu is the Head of Antibiotic Resistance (ReAct) Africa a Civil Society Organization (CSO) organization that articulates the complex nature of antibiotic resistance and its drivers. ReAct plays as a catalyst, advocating for and stimulating country, regional and global engagement on antibiotics resistance by collaborating with broad range of organizations, individuals and stakeholders. Mirfin has been involved in the development of AMR National Action Plans in several African countries. He is a member of several boards and technical working groups including the World Health Organizations Strategic Advisory Group (STAG) on antimicrobial Resistance.

Mirfin is also the Executive Director of the Ecumenical Pharmaceutical Network (EPN) a not for profit, independent organization committed to the provision of quality pharmaceutical services  as a means to achieving global goals. A Registered Clinical pharmacist and Public Health Specialist with 20+ years of proven experience in public health, pharmaceutical supply chain management, clinical management, logistics and regulatory pharmacy practice experience. His experience also includes spearheading successful pooled procurement of pharmaceuticals & medical commodities at country and regional level, contract management, co-technical regional and global experience, quality assurance, organization strategy evaluation and development . He has an adept knowledge in resource mobilization, working with partners, data analysis, drug utilization review, operational research and capacity building.

Mirfin is also passionate about equitable access to quality-assured medicines and  the inclusion and participation of Church Health Facilities within the global health agenda serving in hard to rich areas.

SEDRIC secretariat team

Francesca Chiara

Head of Secretariat

Francesca is the Science Officer in Wellcome’s Drug-resistant Infections team at Wellcome. She oversees a number of projects that focus on the development of new antibiotics, the characterisation of disease burden, and the coordination of drug-resistant infection epidemiology and surveillance activities. She has also contributed to the development of Wellcome’s drug-resistant infection strategy.

Francesca joined Wellcome in 2015 as a business development analyst, managing a portfolio of product development projects. Previously, she was a consultant at Archimedes IP and a postdoctoral research fellow at King’s College London. 

She has a PhD in Neuroscience from University College London and a Research Master’s in Medical and Pharmaceutical Biotechnology from Vita-Salute San Raffaele University, Milan.

Jamie Nunn

Secretariat Officer

Jamie is part of the Drug Resistant Infections team at Wellcome Trust. He previously worked at Oxford Policy Management in the Project Support Unit and as a Project Evaluator in East Africa, conducting monitoring and evaluation work for GlobalGiving UK. Jamie recently completed his master’s in Health Policy, Planning and Financing, awarded jointly by the London School of Economics and Political Science and the London School of Hygiene and Tropical Medicine. 

Become a member

Are you working in AMR surveillance and epidemiology? Join SEDRIC today to start communicating and collaborating with our community of experts.